Global Active Pharmaceutical Ingredient (API) Market Size, Share & Trends Analysis Report 2019-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Active
Pharmaceutical Ingredient (API) Market Size, Share & Trends Analysis
Report By Type of Synthesis (Biotech, Synthetic), By Type of
Manufacturer (Captive, Merchant), By Application, By Region, And Segment
Forecasts, 2019 – 2026” report has been added to ResearchAndMarkets.com’s
offering.

The global active pharmaceutical ingredient (API) market size is
expected to reach at USD 268.12 billion by 2026 registering a CAGR of
6.8%

Rising trend of outsourcing APIs and growing prevalence of various
target diseases, such as cancer, Cardiovascular Disease (CVDs) are
anticipated to boost the market. Huge capital is required in API
production as the process needs extremely systematic protocols.
Pharmaceutical companies can actually benefit from outsourcing API
production, as it eliminates the need for installing expensive
manufacturing units. Moreover, strategic outsourcing enables companies
to focus on their core competencies, ultimately resulting in increased
productivity. These factors are also estimated to drive the demand in
future.

Growing geriatric population across the globe is also likely to
contribute to the market expansion. Estimates published by the WHO
suggest that the global base of population pertaining to the age group
of 65 years and above is expected to rise from 7% in 2000 to 16% in
2050. Latin America, in particular, is projected to witness fastest
growth, in terms of geriatric population, followed by Asia (66%), Africa
(64%), North America (41%), and Europe (23%).

Patent expiration of blockbuster drugs, growing outsourcing activities
due to high manufacturing costs, and stringent regulations for API
production are expected to intensify the market competition. As part of
strategic geographic expansion, many companies are setting up
manufacturing plants in the developing regions like Asia Pacific.

Further key findings from the study suggest:

• Synthetic APIs held the largest share of the API market in 2018 owing
  to easy availability of raw materials and easier protocols for
  synthesis of these molecules
• Biotech APIs are estimated to register the highest CAGR over the
  forecast years due to rising demand for biopharmaceuticals and higher
  efficiency of these molecules
• Captive manufacturers led the market owing to intensive capitalization
  of major key players in development of high-end manufacturing
  facilities
• Merchant manufacturers segment is expected to be the fastest-growing
  segment over the forecast period
• Generic APIs are expected to register a lucrative CAGR over the
  forecast period on account of factors, such as expiration of patents
  of branded drugs and lower cost
• Cardiology segment led the overall market in 2018. Increasing
  prevalence of target diseases worldwide and high demand for
  fast-acting drugs are some of the key factors responsible for the
  segment growth
• North America held the largest market share in 2018. Asia Pacific is
  estimated to be the fastest-growing region expanding at a CAGR of 8.2%
  over the estimated period

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

2.1 API Market Outlook

2.2 API Market: Segment Outlook

2.3 API Market: Competitive Insights

2.4 Market Summary

Chapter 3 Market Variables, Trends & Scope

3.1 Market Lineage Outlook

3.1.1 Parent Market Outlook

3.2 Penetration and Growth Prospect Mapping

Chapter 4 Market Dynamics

4.1 Market Driver Analysis

4.1.1 Growing Geriatric Population Base

4.1.2 Growing Prevalence Of Target Diseases Such As Hospital Acquired
Infections, Genetic, Cardiovascular And Neurological Diseases

4.1.3 Increasing Preference For Targeted Therapy Approach In Cancer
Treatment

4.1.4 Increasing Preference For Outsourcing APIs

4.2 Market Restraint Analysis

4.2.1 Large Capital Investments And Production Cost

4.2.2 Stringent Safety And Handling Regulations Regarding APIs

Chapter 5 API Market Analysis Tools

5.1 Industry Analysis – Porter’s

5.2 PESTEL Analysis

5.3 Major Deals & Strategic Alliances Analysis

Chapter 6 API Market – Competitive Analysis

6.1 Recent Developments & Impact Analysis, By Key Market Participants

6.2 Company/Competition Categorization (Key innovators, Market leaders,
Emerging players)

6.3 Public Companies

6.4 Private Companies

Chapter 7 API Molecules Outlook

7.1 Global Sales (2014 – 2017)

7.2 Companies With Leading Market Position For API Molecules

7.2.1 Amoxicillin

7.2.2 Azithromycin

7.2.3 Bleomycin

7.2.4 Caspofungin

7.2.5 Clarithromycin

7.2.6 Clavulanic Acid

7.2.7 Clindamycin

7.2.8 Compactin (Mevastatin)

7.2.9 Cyclosporin

7.2.10 Dactinomycin

7.2.11 Daptomycin

7.2.12 Demeclocycline

7.2.13 Doxycycline

7.2.14 Erythromycin

7.2.15 Ivermectin (Avermectin)

7.2.16 Lovastatin

7.2.17 Micafungin

7.2.18 Minocycline

7.2.19 Mitomycin

7.2.20 Mycophenolic Acid

7.2.21 Pneumocandin B0

7.2.22 Polymyxin

7.2.23 Pravastatin

7.2.24 Rapamycin (Sirolimus)

7.2.25 Simvastatin

7.2.26 Steroids

7.2.27 Tacrolimus

7.2.28 Tetracycline

7.2.29 Tigecycline

7.2.30 Tobramycin

7.2.31 Vancomycin

7.3 Comparative Price Analysis Of The Above-Mentioned Molecules

Chapter 8 Type Of Synthesis Business Analysis

8.1. Definitions & Scope

8.2. Type of Synthesis Market Share Analysis, 2018 & 2026

8.3. API Market, by Type of Synthesis, 2014 to 2026

8.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the
following,

8.5 Biotech API

8.5.1 Biotech API Market, 2014 – 2026 (USD Billion)

8.5.2 Monoclonal Antibodies

8.5.3 Recombinant Proteins

8.5.4 Vaccines

8.6 Synthetic API

Chapter 9 Type Of Manufacturer Business Analysis

9.1. Definitions & Scope

9.2. Type of Manufacturer Market Share Analysis, 2018 & 2026

9.3. API Market, by Type of Manufacturer, 2014 to 2026

9.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the
following,

9.5 Captive API

9.6 Merchant API

Chapter 10 Type Business Analysis

10.1. Definitions & Scope

10.2. Type Market Share Analysis, 2018 & 2026

10.3. API Market, by Type, 2014 to 2026

10.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the
following,

10.5 Generic APIs

10.6 Innovative APIs

Chapter 11 Application Business Analysis

11.1. Definitions & Scope

11.2. Application Market Share Analysis, 2018 & 2026

11.3. API Market, by Application, 2014 to 2026

11.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the
following,

11.5 Cardiology

11.6 Oncology

11.7 Cns & Neurology

11.8 Orthopedics

11.9 Endocrinology

11.10 Pulmonology

11.11 Gastroenterology

11.12 Nephrology

11.13 Ophthalmology

11.14 Others

Chapter 12 Application, By Type Business Analysis (Cross-Matrix)

12.1. Definitions & Scope

12.2. Application Market Share Analysis, 2018 & 2026

12.3. API Market, by Application, 2014 to 2026

12.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the
following,

12.5 Cardiology

12.6 Oncology

12.7 CNS & Neurology

12.8 Orthopedics

12.9 Endocrinology

12.10 Pulmonology

12.11 Gastroenterology

12.12 Nephrology

12.13 Ophthalmology

12.14 Others

Chapter 13 API Market: Regional Estimates & Trend Analysis

Chapter 14 Competitive Landscape

• Abbvie, Inc.
• Boehringer Ingelheim International Gmbh
• Bristol-Myers Squibb Company
• Cipla Inc.
• Merck & Co., Inc.
• Albemarle Corporation
• Aurobindo Pharma
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries, Ltd.
• Dr. Reddy’S Laboratories Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/pg6eku

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Drug
Discovery, Pharmaceutical
Intermediates